Background: T1D management and control in the year after diagnosis often establish long-term patterns for pediatric patients. Disparities in HbA1c based on race, ethnicity, and socioeconomic status (SES) are documented in the pediatric literature; yet there is limited description of the timeline in which these disparities appear.

Study Design: We conducted a retrospective chart review of patients diagnosed with T1D at a tertiary children’s hospital between 1/1/16 and 2/20/20 who received follow-up care for at least 1 year. Using zip-code level geocoding, we obtained community-level SES data based on American Community Survey (ACS) measures and classified patients according to the percent of families in census tract living in poverty, defined as 200% of the federal poverty level (FPL) .

Results: Of 758 patients, 15.6% (median, IQR 10.53, 24.01) of households were living in poverty; poor patients were defined as those in the upper quartile (>24.0% of households living below 200% of FPL) and rich patients in the lower quartile (<10.5%) . Patients from households in poor communities had higher HbA1c levels compared with their rich counterparts from baseline to 1-year post-diagnosis, although statistical differences emerged after 9 months between poor vs. rich groups: baseline 11.5% vs. 11.2%, p=0.10; 3 months 7.4% vs. 7.3%, p=0.62; 6 months 7.5% vs. 7.3%, p=0.24) ; 9 months 8.1% vs. 7.6%, p=0.01; and 1 year 8.2% vs. 7.8%, p=0.05.

Discussion: These data highlight the early origin of disparities in glycemic control in pediatric patients with T1D based on community-level SES. Understanding the time course of these disparate outcomes helps to inform the need for early intervention, particularly in low-income groups, to provide support likely needed to optimize glycemic control and long-term health outcomes. Further research can assess the overlapping axes of disparities that include race, ethnicity, and education level.


E.S.Tremblay: None. E.Liu: None. L.M.Laffel: Advisory Panel; Medtronic, Roche Diabetes Care, Consultant; Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompé, Insulet Corporation, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Provention Bio, Inc.


NIDDK (K12DK094721)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at